Golden Recursion Inc. logoGolden Recursion Inc. logo
Advanced Search
Aperture Venture Partners

Aperture Venture Partners

Aperture Venture Partners is a New York-based venture capital focused on medical device, pharmaceutical, healthcare, and diagnostic sectors.

Company Overview

Aperture Venture Partners is a venture capital group focused primarily on the healthcare and healthy living industries. Initial investment size ranges between $1 million and $5 million and they invest nationally.

History

Aperture invests in consumer goods, medical device, biopharmaceutical, biotechnology, healthcare information technology services and diagnostic sectors. The firm was founded in 2002 by Eric H. Sillman and Paul E. Tierney, Jr.

The firm works exclusively in the healthcare industry. Aperture's principals have been entrepreneurs in the healthcare and investment industries. They have invested more than $1 billion and founded companies that have had combined revenues greater than $2 billion.

Investments

Aperture Venture Partners has raised a total of $49.2M in a single venture fund, Aperture Venture Partners III, L.P. This fund was announced on Dec 31, 2014, and raised a total of $49.2M. The firm has made 34 investments, one of which was on Sep 14, 2018, when they invested $45M in ENDOTRONIX. Aperture Venture Partners has had 15 exits, the most notable ones including Avedro, Inspire Medical Systems, and Aclaris Therapeutics. The firm has $6.4M in revenue annually.

Investment strategy

Aperture Venture Partners, LLC is a venture capital firm specializing in early-stage investments. It seeks to invest in the healthcare and healthy living industries. Within the healthcare industry, the firm invests in biopharmaceutical, biotechnology, healthcare services, healthcare information technology, diagnostics, drug discovery/delivery, and medical devices. Its investments in the healthy living category include companies that offer products or services in the areas of personal care; weight management; complementary and alternative medicines; vitamins, minerals, and supplements; beverages; sporting goods; apparel; retail; and travel. The firm seeks to invest in companies based in the West Coast and North Eastern United States. It typically invests between $1 million and $5 million in its portfolio companies. The firm seeks to be the lead investor and can also co-invest.

Timeline

September 14, 2018
ENDOTRONIX

Series D - ENDOTRONIX

$45M

April 27, 2018
V-Wave

Series C - V-Wave

$70M

April 26, 2018
Cardiac Dimensions

Series B - Cardiac Dimensions

$39M

February 26, 2018
ENDOTRONIX

Series C - ENDOTRONIX

$37.1M

August 23, 2017
Channel Medsystems

Series C - Channel Medsystems

$14.1M

August 7, 2017
Neuros Medical

Series A - Neuros Medical

$20M

July 20, 2017
Trevi Therapeutics

Series C - Trevi Therapeutics

$50.5M

November 1, 2016
Biohaven Pharmaceutical

Venture Round - Biohaven Pharmaceutical

$80M

March 15, 2016
Spirox

Series C - Spirox

$45M

September 9, 2015
Aclaris Therapeutics

Series C - Aclaris Therapeutics

$40M

Invested in

Patents

Funding Rounds Participated In

Further Resources

Title
Author
Link
Type
Date

Aperture Venture Partners - The Friar Files

Mark Vruno

Web

Aperture Venture Partners Archives - MassDevice

MASSDEVICE

Web

Aperture Venture Partners Raising $100M Fund

Wall Street Journal

Web

Avedro Completes $25 Million Series C Financing SCP Vitalife and Aperture Venture Partners join existing investors

Eric Sillman - Aperture Venture Partners General Partner | Signal

Web

References

Golden logo
By using this site, you agree to our Terms & Conditions.